BTK and Waldenstrom macroglobulinemia: Waldenström macroglobulinemia does not always require treatment and can be monitored; however, if treatment is needed, Waldenström macroglobulinemia is usually treated with a combination of anti-CD20 antibody (rituximab), proteasome inhibitor (bortezomib), alkylating agent (chlorambucil or melphalan), and Bruton tyrosine kinase inhibitor (ibrutinib), while AL amyloidosis is usually treated with a combination of a proteasome inhibitor (bortezomib), cyclophosphamide, dexamethasone, and anti-CD38 antibody (daratumumab).2,6,7